Compare EMF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | EMF | MOLN |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.7M | 158.9M |
| IPO Year | N/A | 2021 |
| Metric | EMF | MOLN |
|---|---|---|
| Price | $16.94 | $4.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 70.9K | 3.6K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 6.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $318.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.14 | $3.36 |
| 52 Week High | $21.20 | $5.36 |
| Indicator | EMF | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 31.35 | 34.20 |
| Support Level | $16.13 | $4.04 |
| Resistance Level | $17.03 | $4.07 |
| Average True Range (ATR) | 0.50 | 0.27 |
| MACD | -0.15 | -0.07 |
| Stochastic Oscillator | 4.19 | 0.00 |
Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.